Definitive Healthcare (NASDAQ:DH) Updates Q2 2024 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its second quarter 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.080-0.090 for the period, compared to the consensus earnings per share estimate of 0.090. The company issued revenue guidance of $62.0 million-$63.5 million, compared to the consensus revenue estimate of $65.2 million. Definitive Healthcare also updated its FY 2024 guidance to 0.360-0.380 EPS.

Definitive Healthcare Price Performance

DH traded down $0.18 during trading on Thursday, hitting $5.17. The company’s stock had a trading volume of 3,323,524 shares, compared to its average volume of 643,916. The company has a current ratio of 2.31, a quick ratio of 2.31 and a debt-to-equity ratio of 0.20. Definitive Healthcare has a twelve month low of $4.38 and a twelve month high of $12.45. The business’s fifty day simple moving average is $7.61 and its 200 day simple moving average is $8.27. The firm has a market capitalization of $608.97 million, a price-to-earnings ratio of -2.90, a P/E/G ratio of 6.12 and a beta of 1.41.

Definitive Healthcare (NASDAQ:DH) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.02). The business had revenue of $65.93 million during the quarter, compared to analyst estimates of $66.01 million. Definitive Healthcare had a negative net margin of 80.40% and a positive return on equity of 0.43%. On average, equities research analysts forecast that Definitive Healthcare will post 0.11 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on DH. Needham & Company LLC restated a hold rating on shares of Definitive Healthcare in a research report on Wednesday. Barclays lowered their price objective on Definitive Healthcare from $11.00 to $7.00 and set an equal weight rating on the stock in a research note on Thursday. Canaccord Genuity Group lowered their price objective on Definitive Healthcare from $10.00 to $8.00 and set a hold rating on the stock in a research note on Wednesday. Morgan Stanley lowered Definitive Healthcare from an overweight rating to an equal weight rating and decreased their price target for the company from $11.50 to $9.00 in a research note on Wednesday. Finally, Stifel Nicolaus decreased their price target on Definitive Healthcare from $11.00 to $9.50 and set a buy rating on the stock in a research note on Wednesday. Nine investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of Hold and a consensus target price of $9.94.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.